AstraZeneca signs $39bn deal to acquire Alexion Pharmaceuticals
In a landmark move that’s poised to shake up the world of immunology and rare disease treatments, AstraZeneca has sealed a $39 billion deal to ... Read More
AstraZeneca resumes AZD1222 Covid-19 vaccine trials after safety review
AstraZeneca has announced the resumption of its clinical trials for the AZD1222 Covid-19 vaccine candidate in multiple countries, following confirmation from regulators in the US, ... Read More
AstraZeneca’s AZD7442 to enter Phase 3 clinical trials for Covid-19 prevention and treatment
AstraZeneca has announced the progression of its monoclonal antibody combination, AZD7442, into two pivotal Phase 3 clinical trials. This long-acting antibody (LAAB) combination is being ... Read More
AstraZeneca finalizes AZD1222 Covid-19 vaccine candidate deal with EC
AstraZeneca said that it has finalized a deal with the European Commission (EC) for the delivery of up to 400 million doses of the AZD1222 ... Read More
AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062
AstraZeneca has signed a deal potentially worth up to $6 billion with Daiichi Sankyo for the global development and commercialization for the latter's DS-1062, a ... Read More